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1. INTRODUCTION {#clc23247-sec-0007}
===============

Type I Brugada syndrome (BrS) is presented by a right bundle branch block (RBBB) and coved ST‐segment elevation in precordial leads (V1‐V3), and its clinical relevance lies in the fact that patients have a pronounced risk to develop malignant tachyarrhythmias.[1](#clc23247-bib-0001){ref-type="ref"}, [2](#clc23247-bib-0002){ref-type="ref"} The prevalence of BrS is estimated to be 5/10 000 inhabitants with a higher prevalence in Japan and Philippines as compared to western countries. Not considering accidents, BrS is the leading cause of death in men \<40 years old, particularly in countries where the syndrome is endemic. Fever and sodium‐channel blockers could potentially unmask BrS, which have led to an expert consensus advising patients with BrS to avoid these drugs and express caution during clinical states such as fever and infections.[3](#clc23247-bib-0003){ref-type="ref"}

Due to the high risk of sudden cardiac death (SCD), it has been recommended that BrS‐patients with a previous episode of sudden cardiac arrest, or those showing inducibility of a sustained ventricular arrhythmia during an electrophysiological study be treated with an implantable cardioverter‐defibrillator (ICD).[4](#clc23247-bib-0004){ref-type="ref"} However, ICD is not always feasible or adequate for every patient.

Although alternative treatments including hydroquinine (HQ) treatment and catheter ablation therapy have demonstrated efficacy in recurrent ventricular arrhythmias,[5](#clc23247-bib-0005){ref-type="ref"} patients who have experienced a prior cardiac arrest or syncopal events secondary to ventricular tachycardia/ventricular fibrillation should undergo ICD implantation.[6](#clc23247-bib-0006){ref-type="ref"}, [7](#clc23247-bib-0007){ref-type="ref"} ICD implantation for primary prevention in BrS patients is controversial.[6](#clc23247-bib-0006){ref-type="ref"}, [8](#clc23247-bib-0008){ref-type="ref"}

The aim of the present study is to observe the long‐term outcome and complication rate of BrS patients, who have received transvenous ICD implantation for primary and secondary prevention.

2. METHODS {#clc23247-sec-0008}
==========

In this analysis, we included all patients diagnosed with BrS and treated with transvenous ICD implantation 2007 and 2018. A total of 747 BrS patients described in 11 research papers, were recruited for our analysis.

BrS was diagnosed only in the presence of a type 1 Brugada pattern on the electrocardiogram (ECG) (coved type), either at baseline or after the administration of a sodium channel blocking agent. The definition of type 1 ECG pattern was the presence of a terminal r′‐wave with a J‐point elevation of at least 0.2 mV, with a slowly descending ST‐segment followed by a negative T‐wave in ≥1 right precordial lead (V~1~‐V~3~). ECG is placed in the fourth, third, or second intercostal space. Sodium channel blockers were administered intravenously over a 10‐minutes period to unmask the diagnostic ECG pattern of BrS in case of a non‐type 1 ECG pattern at baseline. Programming of ICDs of included studies is summarized in Table [S1](#clc23247-supitem-0001){ref-type="supplementary-material"}. Patients were followed annually in a dedicated cardiogenetic outpatient clinic and every 6 to 12 months in the ICD clinic (unless shorter periods of follow‐up were required).

2.1. Data collection of different studies {#clc23247-sec-0009}
-----------------------------------------

Demographic and clinical data including age at diagnosis, gender, family history of SCD or BrS, symptoms before diagnosis, such as atrial arrhythmias and syncope, results of drug testing, affected genotype, electrophysiological study including ventricular stimulation were followed‐up and evaluated. Baseline ICD‐related data included type of ICD. The indication for ICD implantation was reviewed in different studies, with emphasis on basal ECG characteristics, history of recurrent syncope, inducible VT of VF during programmed ventricular stimulation (PVS), family history of SD, and history of VF or aborted cardiac arrest.

2.2. Systematic literature review {#clc23247-sec-0010}
---------------------------------

A literature search (PubMed, Web of Science, Cochrane Library, and Cinahl) was performed with limits including publication dates to 2018, English language and human subjects. Study selection included the criterion BrS and ICD implantation (Figure [1](#clc23247-fig-0001){ref-type="fig"}). Case reports or studies not reporting on outcome of ICD after implantation were excluded.

![flowchart of recruitment criteria of the present study. Finally, 747 patients were included from 11 studies](CLC-42-958-g001){#clc23247-fig-0001}

2.3. Statistics {#clc23247-sec-0011}
---------------

Data are presented as mean ± SD for continuous variables with a normal distribution, median (interquartile range) for continuous variables with a non‐normal distribution, and as frequency (%) for categorical variables. The Kolmogorov‐Smirnov test was used to assess normal distribution. Students *t* test and the Mann‐Whitney *U*‐test were used to compare continuous variables with normal and non‐normal distributions, respectively. The χ² test or Fishers exact test was used to compare categorical variables.

3. RESULTS {#clc23247-sec-0012}
==========

3.1. Demographics {#clc23247-sec-0013}
-----------------

The mean age of patients receiving ICD was 43.1 ± 13.4 with a predominance of males (82.5%). 46.6% of patients showed spontaneous BrS type I and 50.3% demonstrated BrS type I after use of an intravenous sodium channel blocker. Only 21.7% of the patients were asymptomatic. Symptoms were documented as following: 48.3% suffered from recurrent syncope, 15.5% admission due to SCD, and 10.4% atrial arrhythmia, Table [S2](#clc23247-supitem-0002){ref-type="supplementary-material"}.

An electrophysiological study (EP) and PVS was performed in 247 patients to study the inducibility of ventricular tachycardia/ventricular fibrillation, and this was documented in 171 patients (69.2% of cases).

3.2. ICD‐related complications {#clc23247-sec-0014}
------------------------------

The rates of appropriate ICD shocks (18.5%) were similar as compared to inappropriate shocks (18.1%) over a follow‐up interval of 82.3 months (47.5‐110.4). The median time interval to first appropriate shock was 22.3 months, Figure [2](#clc23247-fig-0002){ref-type="fig"}A. The complications are listed as follows: lead failure and fracture (5.4%), lead perforation (0.7%), lead dislodgement (1.7%), infection (3.9%), pain (0.4%), subclavian vein thrombosis (0.3%), pericardial effusion (0.1%), endocarditis (0.1%), psychiatric problem (1.5%), pneumothorax (0.7%), Table [1](#clc23247-tbl-0001){ref-type="table"}. Inappropriate shocks were attributed to supraventricular arrhythmias (13.7%), noise (3.7%) T‐wave oversensing (2.5%) as well as other causes (0.4%), Table [1](#clc23247-tbl-0001){ref-type="table"} and Figure [2](#clc23247-fig-0002){ref-type="fig"}B. Also 3.2% of the patients suffered from an electrical storm. We have compared the data of inappropriate ICD shocks regarding in asymptomatic and symptomatic patients. Asymptomatic BrS patients suffered more significantly from lower rate of inappropriate shocks (Figure [3](#clc23247-fig-0003){ref-type="fig"} A,B). On the other hand, appropriate ICD shocks were significantly more documented in symptomatic patients (Figure [4](#clc23247-fig-0004){ref-type="fig"} A,B).

![Comparison of different studies showing the outcome of implantable cardioverter‐defibrillator (ICD) in 1201 patients](CLC-42-958-g002){#clc23247-fig-0002}

![Rate of appropriate and inappropriate implantable cardioverter‐defibrillator **(**ICD) shocks related to the symptomatic state](CLC-42-958-g003){#clc23247-fig-0003}

![Rate of appropriate and inappropriate implantable cardioverter‐defibrillator (ICD) shocks related to the symptomatic state](CLC-42-958-g004){#clc23247-fig-0004}

###### 

ICD‐related complications of 747 BrS patients

  Study                                                                         Overall       Conte et al[9](#clc23247-bib-0009){ref-type="ref"}   Sarkozy et al[10](#clc23247-bib-0010){ref-type="ref"}   Veltmann et al[11](#clc23247-bib-0011){ref-type="ref"}   Steven et al[12](#clc23247-bib-0012){ref-type="ref"}   Daoulah et al[13](#clc23247-bib-0013){ref-type="ref"}   Miyazakiet al[14](#clc23247-bib-0014){ref-type="ref"}   Son et al[15](#clc23247-bib-0015){ref-type="ref"}   Kamakura et al[16](#clc23247-bib-0016){ref-type="ref"}   Dores et al[17](#clc23247-bib-0017){ref-type="ref"}   Hernandez‐Ojeda et al[18](#clc23247-bib-0018){ref-type="ref"}   Corciaet al 2018
  ----------------------------------------------------------------------------- ------------- ---------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------- ------------------------------------------------------- --------------------------------------------------- -------------------------------------------------------- ----------------------------------------------------- --------------------------------------------------------------- ------------------
  Number of patients                                                            747           176                                                  47                                                      61                                                       33                                                     25                                                      41                                                      69                                                  120                                                      36                                                    104                                                             35
  ICD‐complications, n (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  ICD‐related complications                                                     143 (19.1)    28 (15.9)                                            10 (21.3)                                               13 (21.3)                                                8 (24.2)                                               7 (28)                                                  8 (19.5)                                                0 (0)                                               28 (23.3)                                                2 (5.6)                                               34 (32.7)                                                       5 (14.3)
  Lead failure and fracture                                                     40 (5.4)      14 (8.0)                                             6 (12.8)                                                2 (3.3)                                                  2 (6.1)                                                1 (4)                                                   4 (9.8)                                                 0 (0)                                               10 (8.3)                                                 1 (2.8)                                               12 (11.5)                                                       3 (8.6)
  Lead perforation                                                              5 (0.7)       0 (0)                                                0 (0)                                                   0 (0)                                                    0 (0)                                                  0 (0)                                                   2 (4.9)                                                 0 (0)                                               3 (2.5)                                                  0 (0)                                                 0 (0)                                                           0 (0)
  Lead dislogement                                                              13 (1.7)      7 (4.0)                                              0 (0)                                                   0 (0)                                                    0 (0)                                                  1 (4)                                                   1 (2.4)                                                 0 (0)                                               2 (1.7)                                                  0 (0)                                                 0 (0)                                                           1 (2.9)
  Pulse generator migration                                                     5 (0.7)       2 (1.1)                                              1 (2.1)                                                 0 (0)                                                    0 (0)                                                  0 (0)                                                   0 (0)                                                   0 (0)                                               0 (0)                                                    0 (0)                                                 1 (1.0)                                                         1 (2.9)
  Infection                                                                     29 (3.9)      5 (9.1)                                              0 (0)                                                   1 (1.6)                                                  2 (6.1)                                                0 (0)                                                   3 (7.3)                                                 0 (0)                                               10 (8.3)                                                 1 (2.8)                                               7 (6.7)                                                         0 (0)
  Pain                                                                          3 (0.4)       0 (0)                                                0 (0)                                                   0 (0)                                                    0 (0)                                                  0 (0)                                                   0 (0)                                                   0 (0)                                               3 (2.5)                                                  0 (0)                                                 0 (0)                                                           0 (0)
  Subclavian vein thrombosis                                                    2 (0.3)       0 (0)                                                0 (0)                                                   0 (0)                                                    1 (3.0)                                                0 (0)                                                   1 (2.4)                                                 0 (0)                                               0 (0)                                                    0 (0)                                                 0 (0)                                                           0 (0)
  Pericardial effusion                                                          1 (0.1)       0 (0)                                                0 (0)                                                   0 (0)                                                    1 (3.0)                                                0 (0)                                                   0 (0)                                                   0 (0)                                               0 (0)                                                    0 (0)                                                 0 (0)                                                           0 (0)
  Endocarditis                                                                  1 (0.1)       0 (0)                                                0 (0)                                                   0 (0)                                                    0 (0)                                                  0 (0)                                                   0 (0)                                                   0 (0)                                               0 (0)                                                    0 (0)                                                 1 (1.0)                                                         0 (0)
  Cardiac perforation                                                           1 (0.1)       0 (0)                                                0 (0)                                                   0 (0)                                                    0 (0)                                                  0 (0)                                                   0 (0)                                                   0 (0)                                               0 (0)                                                    0 (0)                                                 1 (1.0)                                                         0 (0)
  Battery depletion                                                                           1.27 ± 0.5 per patient                               0 (0)                                                   10 (16.4)                                                4 (12.1)                                               0 (0)                                                   0 (0)                                                   0 (0)                                               0 (0)                                                    0 (0)                                                 73 (70.2)                                                       0 (0)
  Psychiatric problem                                                           7 (1.5)       0 (0)                                                0 (0)                                                   0 (0)                                                    0 (0)                                                  5 (20)                                                  2 (4.9)                                                 0 (0)                                               0 (0)                                                    0 (0)                                                 0 (0)                                                           0 (0)
  High defibrillation threshold                                                 3 (0.4)       0 (0)                                                2 (4.2)                                                 0 (0)                                                    1 (3.0)                                                0 (0)                                                   0 (0)                                                   0 (0)                                               0 (0)                                                    0 (0)                                                 0 (0)                                                           0 (0)
  Pneumothorax                                                                  5 (0.7)       2 (1.1)                                              1 (2.1)                                                 0 (0)                                                    0 (0)                                                  0 (0)                                                   0 (0)                                                   0 (0)                                               0 (0)                                                    0 (0)                                                 2 (1.9)                                                         0 (0)
  Shock data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Inappropriate shocks, n (%)                                                   135 (18.1)    33 (18.8)                                            17 (36.2)                                               5 (8.2)                                                  7 (21.1)                                               3 (12)                                                  10 (24.4)                                               15 (22.1)                                           21 (17.5)                                                8 (22.2)                                              9 (8.7)                                                         7 (20.0)
  Cause for IS, n (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Supraventricular arrhythmia, such as sinus tachycardia, atrial flutter, SVT   102 (13.7)    27 (15.3)                                            19 (40.4)                                               1 (1.6)                                                  5 (15.2)                                               1 (4)                                                   \>1 (2.4)                                               6 (8.7)                                             32 (26.7)                                                5 (13.9)                                              3 (2.9)                                                         2 (5.7)
  Sinus tachycardia                                                             27 (3.6)      5 (2.8)                                              8 (17.0)                                                0 (0)                                                    0 (0)                                                  1 (4)                                                   0 (0)                                                   Yes                                                 6 (5.0)                                                  5 (13.9)                                              1 (1.0)                                                         1 (2.9)
  SVT                                                                           32 (4.3)      0 (0)                                                6 (12.8)                                                0 (0)                                                    0 (0)                                                  0 (0)                                                   ?                                                       No                                                  26 (21.7)                                                0 (0)                                                 0 (0)                                                           
  Atrial fibrillation                                                           28 (3.7)      15 (8.5)                                             3 (6.4)                                                 1 (1.6)                                                  5 (15.2)                                               0 (0)                                                   \>1 (2.4)                                               Yes                                                 0 (0)                                                    0 (0)                                                 2 (1.9)                                                         1 (2.9)
  Atrial flutter                                                                3 (0.4)       0 (0)                                                2 (4.2)                                                 0 (0)                                                    0 (0)                                                  0 (0)                                                   0 (0)                                                   Yes                                                 0 (0)                                                    0 (0)                                                 0 (0)                                                           0 (0)
  Noise                                                                         28 (3.7)      7 (4.0)                                              5 (10.6)                                                0 (0)                                                    0 (0)                                                  1 (4)                                                   0 (0)                                                   2 (2.9)                                             5 (4.2)                                                  0 (0)                                                 5 (4.8)                                                         3 (8.6)
  T‐wave oversensing                                                            19 (2.5)      6 (3.4)                                              1 (2.1)                                                 4 (6.6)                                                  0 (0)                                                  1 (4)                                                   \>1 (2.4)                                               0 (0)                                               3 (2.5)                                                  0 (0)                                                 1 (1.0)                                                         2 (5.7)
  Abnormal sensing                                                              2 (0.3)       0 (0)                                                0 (0)                                                   0 (0)                                                    0 (0)                                                  0 (0)                                                   0 (0)                                                   2 (2.9)                                             0 (0)                                                    0 (0)                                                 0 (0)                                                           0 (0)
  NSVT                                                                          1 (0.1)       0 (0)                                                1 (2.1)                                                 0 (0)                                                    0 (0)                                                  0 (0)                                                   0 (0)                                                   0 (0)                                               0 (0)                                                    0 (0)                                                 0 (0)                                                           0 (0)
  Premature ventricular capture beats                                           2 (0.3)       0 (0)                                                0 (0)                                                   0 (0)                                                    2 (6.1)                                                0 (0)                                                   0 (0)                                                   0 (0)                                               0 (0)                                                    0 (0)                                                 0 (0)                                                           0 (0)
  Unknown                                                                       1 (0.1)       0 (0)                                                0 (0)                                                   0 (0)                                                    1 (3.0)                                                0 (0)                                                   0 (0)                                                   0 (0)                                               0 (0)                                                    0 (0)                                                 0 (0)                                                           0 (0)
  Others                                                                        3 (0.4)       0 (0)                                                0 (0)                                                   0 (0)                                                    0 (0)                                                  0 (0)                                                   0 (0)                                                   0 (0)                                               3 (2.5)                                                  0 (0)                                                 0 (0)                                                           0 (0)
  Management of IS, n (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Pulmonary vein isolation                                                      4 (0.5)       3 (1.7)                                              0 (0)                                                   0 (0)                                                    0 (0)                                                  0 (0)                                                   0 (0)                                                   0 (0)                                               0 (0)                                                    0 (0)                                                 0 (0)                                                           1 (2.9)
  Drug treatment with sotalol                                                   10 (1.3)      10 (5.7)                                             0 (0)                                                   0 (0)                                                    0 (0)                                                  0 (0)                                                   0 (0)                                                   0 (0)                                               0 (0)                                                    0 (0)                                                 0 (0)                                                           0 (0)
  Drug treatment with sotalol+betablocker                                       2 (0.3)       2 (1.1)                                              0 (0)                                                   0 (0)                                                    0 (0)                                                  0 (0)                                                   0 (0)                                                   0 (0)                                               0 (0)                                                    0 (0)                                                 0 (0)                                                           0 (0)
  Hydroquinidine                                                                1 (0.1)       0 (0)                                                0 (0)                                                   1 (1.6)                                                  0 (0)                                                  0 (0)                                                   0 (0)                                                   0 (0)                                               0 (0)                                                    0 (0)                                                 0 (0)                                                           0 (0)
  Appropriate shock data, n (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Appropriate shock                                                             138 (18.5)    28 (15.9)                                            7 (14.9)                                                7 (11.5)                                                 2 (6.1)                                                3 (12)                                                  5 (12.2)                                                19 (27.5)                                           31 (25.8)                                                7 (19.4)                                              21 (20.2)                                                       8 (22.9)
  Electrical storm                                                              24 (3.2)      4 (2.3)                                              0 (0)                                                   0 (0)                                                    0 (0)                                                  ≥1 (4)                                                  0 (0)                                                   0 (0)                                               11 (9.2)                                                 4 (11.1)                                              1 (1.0)                                                         3 (8.6)
  Quinidine treatment                                                           21 (2.8)      2 (1.1)                                              2 (4.3)                                                 1 (1.6)                                                  0 (0)                                                  1 (4)                                                   0 (0)                                                   0 (0)                                               2 (1.7)                                                  4 (11.1)                                              9 (8.7)                                                         0 (0)
  Time to appropriate shock, mean (months)                                      22.3          20.7 ± 25.9                                          13 (3 days -- 4 years)                                  11 ± 12.6                                                ‐                                                      17 ± 26                                                 ‐                                                       16 ± 22                                             ‐                                                        17 (3‐51 months)                                      48.8 ± 54                                                       7.2
  Follow‐up time, mean (months)                                                 83.8 ± 57.3   83.8 ± 57.3                                          47.5                                                    47.6                                                     94.8 ± 43.2                                            41.2 ± 17.6                                             76 (51 to 98)                                           59 ± 46                                             102 ± 68                                                 74 ± 40                                               110.4 ± 60                                                      88 (7‐238)

Abbreviations: ICD, implantable cardioverter defibrillator.; IS, inappropriate shock; n.p., not performed; NSVT, non‐sustained ventricular tachycardia; SCD, sudden cardiac death; SVT, supraventricular tachycardia; VF, ventricular fibrillation; VT, ventricular tachycardia; ‐, no information.

3.3. Management of complications {#clc23247-sec-0015}
--------------------------------

Pulmonary vein isolation was carried out in 0.5% of the patients. About 1.3% received drug treatment with sotalol or sotalol with beta‐blocker (0.3%) and 0.1% received HQ. Electrical storm was documented in 24 patients (3.2%). Therefore, 21 (2.8%) patients were treated with HQ to manage electrical storm, Table [1](#clc23247-tbl-0001){ref-type="table"} and Figure [2](#clc23247-fig-0002){ref-type="fig"}C.

4. DISCUSSION {#clc23247-sec-0016}
=============

We have described the short‐ and long‐term ICD outcomes in 747 BrS patients including 11 defined studies and summarized the followingup to 18.5% and 3.2% of all appropriate ICD therapies and electrical storms are documented, respectively with a higher rate in symptomatic BrS patientsthe incidence of ICD‐related complications, such as inappropriate shocks are common with a rate of up to 18.1% with a higher presence in symptomatic patientsmanagement of ICD‐related complications remains challenging. However, use of HQ and ablation strategies may be helpful in managing such complications.

ICD therapy is suggested in survivors of SCD,[6](#clc23247-bib-0006){ref-type="ref"} however, data have suggested that its use may be associated with significant adverse events.[18](#clc23247-bib-0018){ref-type="ref"} The primary finding of this systematic analysis is that patients with an ICD implantation for BrS have considerable risk for developing potentially life‐threatening ventricular arrhythmias (18.5%) over the long‐term, as seen in the median follow‐up of 82.3 months. However, inappropriate shocks also occurred in 18.1% of the patients and this was essentially dominated by supraventricular arrhythmias, noise and T‐wave oversensing. The rate of some other ICD‐related complications was also quite high. Our data are consisting with the high rate of inappropriate shocks of other patients treated with ICD implantation, such as in the MADIT II and SCDHEFT trial. Whereas the MADIT (Multicenter Automatic Defibrillator Implantation Trial) II trial has presented a lower rate of inappropriate ICD shocks (11.5%), predominated by atrial fibrillation (44%), supraventricular tachycardia (36%), and abnormal sensing (20%), as compared to our data,[19](#clc23247-bib-0019){ref-type="ref"} the SCDHEFT trial, recruiting patients with New York Heart Association (NYHA) class II or III heart failure and a left ventricular ejection fraction of 35% or less, reported a comparable rate of inappropriate shocks (17.4%).[20](#clc23247-bib-0020){ref-type="ref"} Even more in patients with inherited channelopathies including catecholaminergic polymorphic ventricular tachycardia was the rate of inappropriate ICD shocks 24.7%[21](#clc23247-bib-0021){ref-type="ref"} as compared with 11% in inherited long QT syndrome patients predominated by supraventricular tachycardia.[22](#clc23247-bib-0022){ref-type="ref"}

Overall, there is great variation in the reported rate of appropriate therapy in BrS patients. One of the most significant differences between these studies are the incidence of appropriate therapies in previously asymptomatic individuals. Although several authors report no therapy in this group, during an average follow‐up of 2.3 to 7.3 years,[12](#clc23247-bib-0012){ref-type="ref"}, [13](#clc23247-bib-0013){ref-type="ref"}, [23](#clc23247-bib-0023){ref-type="ref"}, [24](#clc23247-bib-0024){ref-type="ref"}, [25](#clc23247-bib-0025){ref-type="ref"} other studies report an overall rate of 4% to 13% after an average follow‐up of 3.2 to 9.3 years.[9](#clc23247-bib-0009){ref-type="ref"}, [15](#clc23247-bib-0015){ref-type="ref"}, [26](#clc23247-bib-0026){ref-type="ref"}, [27](#clc23247-bib-0027){ref-type="ref"}, [28](#clc23247-bib-0028){ref-type="ref"} A difference in the study population is the most likely explanation for this observation. Although inappropriate ICD shocks were more documented in symptomatic patients, even more appropriate ICD shocks were also more documented in this group.

BrS and short QT syndrome may be considered similar entities,[29](#clc23247-bib-0029){ref-type="ref"} thus, comparing patient data from these two groups could prove interesting. Whereas in short QT syndrome, inappropriate therapy is more inherent due to the detection of short‐coupled and prominent T waves (in up to 60% of cases); in BrS, supraventricular arrhythmias are often responsible for the inappropriate shocks. Therefore, careful testing of ICD function and adaptation of sensing levels and decay delays without sacrificing correct arrhythmia detection might be essential for short QT syndrome patient.[30](#clc23247-bib-0030){ref-type="ref"} On the other hand, in BrS, drug treatment and ablation strategies might be more useful to manage inappropriate shocks.[31](#clc23247-bib-0031){ref-type="ref"}, [32](#clc23247-bib-0032){ref-type="ref"}

Although only 15.3% of patients were admitted due to aborted out of hospital cardiac arrest and these received ICD implantations for secondary prevention, asymptomatic patients receiving ICDs for primary prevention also suffered from life‐threatening arrhythmias, which were terminated by appropriate ICD shocks. However, further insights in risk stratification strategies are necessary in BrS to avoid ICD‐related complications.

4.1. Study limitation {#clc23247-sec-0017}
---------------------

This study provides registry data dominated by retrospective studies and, although the authors clinically evaluated all patients, clinical assessment and treatment algorithm was not uniform and consecutively ICD indications were homogeneous throughout the study. Only*SCN5A* mutations were evaluated in the present analysis; excluding the possibility of mutations in other BrS‐related genes. Also, despite the obvious advantages of our recruited studies, novel therapeutic approaches like ventricular ablation and systematic use of HQ were not evaluated. Finally, the role of subcutaneous ICD was not evaluated in the present study.

5. CONCLUSIONS {#clc23247-sec-0018}
==============

Regarding a relevant risk of device‐related complications with a higher rate of inappropriate ICD shocks in symptomatic BrS patients special care during regular follow‐up in specialized cardiogenetic centers may allow the reduction in the number of adverse events.
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